Photodiagnosis and Photodynamic Therapy
Volume 4, Issue 3 , Pages 197-201 , September 2007

Comparison of aminolevulinic acid (ALA)-thermogel-PDT with methyl-ALA-thermogel-PDT in basal cell carcinoma

  • Peter Schleier, PdD

      Affiliations

    • Department of Maxillofacial Surgery/Plastic Surgery, Friedrich Schiller University Jena, Germany
    • Corresponding Author InformationCorresponding author at: Department of Orofacial Surgery, University of Stavanger, Armauer Hansensvei 20, 4017 Stavanger, Norway. Tel.: +47 515183555; fax: +47 51518337.
    • ,
  • Alexander Berndt

      Affiliations

    • Institute of Pathology, Friedrich Schiller University Jena, Germany
    • ,
  • Susann Kolossa

      Affiliations

    • Private Practice, Erfurt, Germany
    • ,
  • Witold Zenk

      Affiliations

    • Department of Maxillofacial Surgery/Plastic Surgery, Friedrich Schiller University Jena, Germany
    • ,
  • Peter Hyckel

      Affiliations

    • Department of Maxillofacial Surgery/Plastic Surgery, Friedrich Schiller University Jena, Germany
    • ,
  • Stefan Schultze-Mosgau

      Affiliations

    • Department of Maxillofacial Surgery/Plastic Surgery, Friedrich Schiller University Jena, Germany

References 

  1. Ehrenfeld M, und Prein J. In:  Schwenzer N,  Ehrenfeld M, Spezielle Chirurgie  editor. Tumors at maxillo-facial area. ed 6. Stuttgart, New York: Thieme; 2002;p. 125–126
  2. Wong SM, Strange RC, Lear JT. Basal cell carcinoma. Br Med J. 2003;327:794–798
  3. Kopf AW. Computer analysis of 3531 basal cell carcinomas of the skin. J Dermatol. 1997;6:267–281
  4. Rhodes LE, de Rie M, Enström Y, et al. Photodynamic therapy using methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2004;140:17–23
  5. Park AJ. Basal cell carcinomas: do they need to be followed up?. J R Coll Surg Edinb. 1994;39:209–211
  6. Schleier P, Hyckel P, Berndt A, et al. Photodynamic therapy of virus-associated epithelial tumours of the face in organ transplant recipients. J Cancer Res Clin Oncol. 2004;130:279–284
  7. Ell C, Baumgartner R, Gossner L. Photodynamic treatment. Dt Ärztebl 2000;97:3337–43.
  8. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990;6:143–148
  9. Peng Q, Warloe T, Berg K. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer. 1997;79:2282–2308
  10. Szeimies RM, Abels C, Fritsch C. Wavelength dependency of photodynamic effects after sensitization with 5-aminolevulinic acid in vitro and in vivo. J Invest Dermatol. 1995;105:672–677
  11. Fritsch C, Batz J, Bolsen K, et al. Ex vivo application of δ-aminolevulinic acid induces high and specific porphyrin levels in human skin tumors: possible basis for selective photodynamic therapy. Photochem Photobiol. 1997;66:114–118
  12. Casas A, Fukuda H, Di Venosa G, Del Cbatlle AM. The influence of the vehicle on the synthesis of porphyrins after topical application of 5-aminolaevulinic acid. Implications in cutaneous photodynamic sensitisation. Br J Dermatol. 2000;143:564–572
  13. Morton CA, Whitehurst C, Mosely H, Moore JV, Mackie RM. Development of an alternative light source to lasers for photodynamic therapy, III: clinical evaluations in the treatment of pre-malignant non-melanoma skin cancer. Lasers Med Sci. 1995;10:165–171
  14. Sharareh A, Paul A, McCarron RF, Donnelly AD, Woolfson K, McKenna G. Evaluation of the penetration of 5-aminolevulinic acid through basal cell carcinoma: a pilot study. Exp Dermatol. 2004;13:445–545
  15. De Blois AW, Grouls RJ, Ackerman EW, Wijdeven WJ. Development of a stable solution of 5-aminolevulinic acid for intracutaneous injection in photodynamic therapy. Lasers Med Sci. 2002;17:208–215
  16. Berg K, Anholt H, Bech O, Moan J. The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Br J Cancer. 1996;74:688–697
  17. Choudry K, Brooke RCC, Farrar W, Rhodes LE. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol. 2003;149:124–130
  18. Clark C, Bryden A, Dawe R, et al. Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed. 2003;19:134–141
  19. Müller S, Walt H, Dobler-Girdziunaite D. Enhanced photodynamic effects using fractionated laser light. J Photochem Photobiol B. 1998;42:67–70
  20. Morton CA. Methyl aminolevulinate (Metvix®) photodynamic therapy—practical pearls. J Dermatol Treat. 2003;14:23–26
  21. Gaulloer JM, Berg K, Peng Q. Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res. 1997;57:1481–1486
  22. Chen HM, Chen CT, Yang H, et al. Successful treatment of oral verrucous hyperplasia with topical 5-aminolevulinic acid-mediated photodynamic therapy. Oral Oncol. 2004;40:630–637
  23. Soler AM, Warloe T, Tausjø J, Giercksky KE. Photodynamic therapy of residual or recurrent basal cell carcinoma after radiotherapy using topical 5-aminolevulinic acid or methylester aminolevulinic acid. Acta Oncol. 2000;39:605–609
  24. Wang X. Pharmacokinetics and selectivity of ALA-induced porphyrin synthesis after topical application of hexyl-aminolevulinic-acid in cervical intraepithelial neoplasia. Medical dissertation. University of Munich; 2004.
  25. Rowe DE, Carrol RJ, Day CL. Long term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15:315–328
  26. Cappugi P, Campolmi P, Mavilia L, Prignano F, Rossi R. Topical 5-aminolevulinic acid and photodynamic therapy in dermatology: a minireview. J Chem. 2001;13:494–502
  27. Wang I, Bendsoe N, Klinteberg CA. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 2001;144:832–840
  28. van den Akker JT, Holroyd JA, Vernon DI, Sterenborg HJ, Brown SB. Comparative in vitro percutaneous penetration of 5-aminolevulinic acid and two of its esters through excised hairless mouse skin. Lasers Surg Med. 2003;33:173–181
  29. Ahmadi S, McCarron PA, Donnelly RF, Woolfson AD, McKenna K. Evaluation of the penetration of 5-aminolevulinic acid through basal cell carcinoma: a pilot study. Exp Dermatol. 2004;13:445–451
  30. Viniciullo C, Elliott T, Gebauer K. Photodynamic therapy using methyl aminolevulinate in patients with basal cell carcinoma. J Am Acad Dermatol. 2004;50:124–126
  31. Peng Q, Warloe T, Moan J, et al. Distribution of 5-aminolevulinic acid-induced porphyrins in nodulo-ulcerative basal cell carcinoma. Photochem Photobiol. 1995;62:901–906
  32. Jichlinski P, Leisinger HJ. Photodynamic therapy in superficial bladder cancer: past, present and future. Urol Res. 2001;29:396–405
  33. Gronlund-Pakkanen S, Pakkanen TM, Koski E, et al. Effect of photodynamic therapy on urinary bladder function: an experimental study with rats. Urol Res. 2001;29:205–209
  34. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6:535–545
  35. Fritsch C, Lehmann P, Stahl W, et al. Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of δ-aminolaevulinic acid. Br J Cancer. 1999;79:1603–1608
  36. Haller JC, Cairnduff F, Slack G, et al. Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy. Br J Dermatol. 2000;143:1270–1274
  37. Cook RJ, Lee KA, Li H. Non-inferiority trial design for recurrent events. Stat Med. 2007;4:378–386

PII: S1572-1000(07)00064-6

doi: 10.1016/j.pdpdt.2007.04.004

Photodiagnosis and Photodynamic Therapy
Volume 4, Issue 3 , Pages 197-201 , September 2007

Article Tools